This is a working overview of investigational status, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-11 and is reviewed periodically as new material appears.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
| Property | Value | Notes |
|---|---|---|
| Storage temperature (solid) | -20 °C or below | Freezer storage with desiccant |
| Solubility | Soluble in water and aqueous buffer | Careful dissolution needed at higher concentrations |
| Appearance | White to off-white lyophilised powder | Visual inspection for discolouration |
| Primary analytical method | Reversed-phase HPLC with UV detection | Paired with mass spectrometry for identity |
| Common synonyms | Triple-agonist peptide; GLP-1/GIP/glucagon agonist | Naming varies across the literature |
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
AMBP, APLP2, APP COL6A3, COL7A1, COL28A1 PAPLN, EPPIN, SPINT1, SPINT2, SPINT3, SPINT4 TFPI, TFPI2 WFDC6, WFDC8, WFIKKN1, WFIKKN2 Several plant protease inhibitors of the Kunitz family, the Kunitz-STI protein family, include a beta trefoil fold.
A preprohormone is the precursor protein to one or more prohormones, which are in turn precursors to peptide hormones. In general, the protein consists of the amino acid chain that is created by the hormone-secreting cell, before any changes have been made to it. It contains a signal peptide, the hormone(s) itself (themselves), and intervening amino acids. Before the hormone is released from the cell, the signal peptide and other amino acids are removed.
==== Synteny-based approaches ==== Synteny-based approaches use order and relative positioning of genes (or other features) to identify the potential ancestors of candidate de novo genes. Syntenic alignments are anchored by conserved "markers." Genes are the most common marker in defining syntenic blocks, although k-mers and exons are also used. Confirmation that the syntenic region lacks coding potential in outgroup species allows a de novo origin to be asserted with higher confidence. The strongest possible evidence for de novo emergence is the inference of the specific "enabling" mutation(s) that created coding potential, typically through the analysis of smaller sequence regions, termed microsyntenic regions, of closely related species. One challenge in applying synteny-based methods is that synteny can be difficult to detect across longer timescales. To address this, various optimization techniques have been created, such as using exons clustered irrespective of their specific order to define syntenic blocks or algorithms that use well-conserved genomic regions to expand microsyntenic blocks. There are also difficulties associated with applying synteny-based approaches to genome assemblies that are fragmented or in lineages with high rates of chromosomal rearrangements, as is common in insects. Synteny-based approaches can be applied to genome-wide surveys of de novo genes and represent a promising area of algorithmic development for gene birth dating.
Square pyramidal for five-coordination Capped octahedral or capped trigonal prismatic for seven-coordination Dodecahedral or bicapped trigonal prismatic for eight-coordination Capped square antiprismatic for nine-coordination To distinguish between the alternative coordinations for five-coordinated complexes, the τ geometry index was invented by Addison et al. This index depends on angles by the coordination center and changes between 0 for the square pyramidal to 1 for trigonal bipyramidal structures, allowing to classify the cases in between. This system was later extended to four-coordinated complexes by Houser et al. and also Okuniewski et al. In systems with low d electron count, due to special electronic effects such as (second-order) Jahn–Teller stabilization, certain geometries (in which the coordination atoms do not follow a points-on-a-sphere pattern) are stabilized relative to the other possibilities, e.g. for some compounds the trigonal prismatic geometry is stabilized relative to octahedral structures for six-coordination.
== References == Huynh, Ngan Ngoc; Chin-Dusting, Jaye (2006). "Amino Acids, Arginase and Nitric Oxide in Vascular Health". Clinical and Experimental Pharmacology and Physiology. 33 (1–2): 1–8. doi:10.1111/j.1440-1681.2006.04316.x. PMID 16445692. S2CID 45083834. Schmitz, M; Hagemeister, H; Erbersdobler, HF (1991). "Homoarginine labeling is suitable for determination of protein absorption in miniature pigs". The Journal of Nutrition. 121 (10): 1575–80. doi:10.1093/jn/121.10.1575. PMID 1722509. Lin, C. W.; Fishman, W. H. (1972). "L-Homoarginine: an organ-specific, uncompetitive inhibitor of human liver and bone alkaline phosphohydrolases" (PDF). Journal of Biological Chemistry. 247: 3082–3087. doi:10.1016/S0021-9258(19)45215-0. Ryan, W. L.; Wells, I. C. (1964). "Homocitrulline and Homoarginine Synthesis from Lysine". Science. 144 (3622): 1122–7. Bibcode:1964Sci...144.1122R. doi:10.1126/science.144.3622.1122. PMID 14148430. S2CID 2732208. Drechsler, C.; Meinitzer, A.; Pilz, S.; Krane, V.; Tomaschitz, A.; Ritz, E.; Marz, W.; Wanner, C. (2011). "Homoarginine, heart failure, and sudden cardiac death in haemodialysis patients". European Journal of Heart Failure. 13 (8): 852–9. doi:10.1093/eurjhf/hfr056. PMC 3143829. PMID 21791541.
Sources: en.wikipedia.org
It is also expected that thorium-232 should be able to undergo double beta decay, which would produce uranium-232, but this has not yet been observed experimentally. All isotopes from 232U to 236U inclusive have minor cluster decay branches (less than 10−10%), and all these bar 233U, in addition to 238U, have minor spontaneous fission branches; the greatest branching ratio for spontaneous fission is about 5×10−5% for 238U, or about one in every two million decays. The shorter-lived trace isotopes 237U and 239U exclusively undergo beta decay, with respective half-lives of 6.752 days and 23.45 minutes. In total, 28 isotopes of uranium have been identified, ranging in mass number from 214 to 242, with the exception of 220. Among the uranium isotopes not found in natural samples or nuclear fuel, the longest-lived is 230U, an alpha emitter with a half-life of 20.23 days. This isotope has been considered for use in targeted alpha-particle therapy (TAT). All other isotopes have half-lives shorter than one hour, except for 231U (half-life 4.2 days) and 240U (half-life 14.1 hours). The shortest-lived known isotope is 221U, with a half-life of 660 nanoseconds, and it is expected that the hitherto unknown 220U has an even shorter half-life. The proton-rich isotopes lighter than 232U primarily undergo alpha decay, except for 229U and 231U, which decay to protactinium isotopes via positron emission and electron capture, respectively; the neutron-rich 240U, 241U, and 242U undergo beta decay to form neptunium isotopes.
[W]e find that the European Communities did not actually proceed to an assessment, within the meaning of Articles 5.1 and 5.2, of the risks arising from the failure of observance of good veterinary practice combined with problems of control of the use of hormones for growth promotion purposes. The absence of such risk assessment, when considered in conjunction with the conclusion actually reached by most, if not all, of the scientific studies relating to the other aspects of risk noted earlier, leads us to the conclusion that no risk assessment that reasonably supports or warrants the import prohibition embodied in the EC Directives was furnished to the Panel. We affirm, therefore, the ultimate conclusions of the Panel that the EC import prohibition is not based on a risk assessment within the meaning of Articles 5.1 and 5.2 of the SPS Agreement and is, therefore, inconsistent with the requirements of Article 5.1.
=== International === UEFA Cup Winners' Cup Runners-up: 1986–87 (Lost 0–1 to AFC Ajax) UEFA Cup Semi-finalist: 1973–74 International Football Cup (Intertoto Cup) Winners (1): 1965–66 Runners-up: 1964–65
== Synthesis == Routes to isoleucine are numerous. One common multistep procedure starts from 2-bromobutane and diethylmalonate. Synthetic isoleucine was first reported in 1905 by French chemists Bouveault and Locquin.
Sources: en.wikipedia.org
With each successive cycle, the original template strands plus all newly generated strands become template strands for the next round of elongation, leading to exponential (geometric) amplification of the specific DNA target region. The processes of denaturation, annealing and elongation constitute a single cycle. Multiple cycles are required to amplify the DNA target to millions of copies. The formula used to calculate the number of DNA copies formed after a given number of cycles is 2n, where n is the number of cycles. Thus, a reaction set for 30 cycles results in 230, or 1,073,741,824 copies of the original double-stranded DNA target region. Final elongation: This single step is optional, but is performed at a temperature of 70–74 °C (158–165 °F) (the temperature range required for optimal activity of most polymerases used in PCR) for 5–15 minutes after the last PCR cycle to ensure that any remaining single-stranded DNA is fully elongated. Final hold: The final step cools the reaction chamber to 4–15 °C (39–59 °F) for an indefinite time, and may be employed for short-term storage of the PCR products.
Comintern (1919–1943), or Communist International, was an international communist organization based in the Kremlin that advocated world communism. The Comintern intended to 'struggle by all available means, including armed force, for the overthrow of the international bourgeoisie and the creation of an international Soviet republic as a transition stage to the complete abolition of the state'. It was abolished as a conciliatory measure toward Britain and the United States. Comecon, the Council for Mutual Economic Assistance (Russian: Совет Экономической Взаимопомощи, Sovet Ekonomicheskoy Vzaimopomoshchi, СЭВ, SEV) was an economic organization from 1949 to 1991 under Soviet control that comprised the countries of the Eastern Bloc along with several communist states elsewhere in the world. Moscow was concerned about the Marshall Plan, and Comecon was meant to prevent countries in the Soviets' sphere of influence from moving towards that of the Americans and Southeast Asia. Comecon was the Eastern Bloc's reply to the formation in Western Europe of the Organization for European Economic Co-Operation (OEEC), The Warsaw Pact was a collective defence alliance formed in 1955 among the USSR and its satellite states in Eastern Europe during the Cold War. The Warsaw Pact was the military complement to the Comecon, the regional economic organization for the socialist states of Central and Eastern Europe. The Warsaw Pact was created in reaction to the integration of West Germany into NATO.
Necrophagous beetles have evolved many diet-related adaptations. For example, Nicrophorus species have specialized olfactory sensors on their antennae to help them detect carrion. These sensors are sensitive to dimethyl sulphide and other sulfur-containing compounds emitted by bodies after death. Also, Nicrophorus, Necrodes and other necrophagous silphine beetle species are flight-capable, making it easier for them to reach carrion. Nicrophorus and Dermestes species have many defenses against dietary pathogens and toxins too. These include physical traits such as protective gut linings, antibacterial lectins and lysozymes, mutualistic relationships with microbiota bacteria, and behavioral traits such as preferentially selecting fresh carcasses and smearing carcasses with antibacterial and toxin-degrading exudates. Given the often-limited availability of carrion, the ability of these beetles to share this resource with other beetles and defend it against flies and ants is also an advantage. Regarding food preferences and the logistics of carrion use, N. vespilloides and other burying beetles favor small carcasses (e.g. rodents and small birds) as these are easier to transport, clean and conceal from competitors. Diving beetles, scarab beetles and water scavenger beetles have all been observed feeding on amphibian carrion (e.g. granular toads and tree frogs). The scarab beetle Scybalocanthon nigriceps uses its front legs and clypeus to shape frog carrion into pellets for eventual consumption.
Sources: en.wikipedia.org
Mass spectrometry provides the most direct confirmation of molecular mass. Reversed-phase chromatography adds a retention-time signature that supports identity when compared against a reference standard. No single method is sufficient on its own.
Cool, dry conditions with desiccant are standard for the solid form. Long-term storage is usually at freezer temperatures, with short-term handling at refrigerator temperature. Vials are allowed to equilibrate before opening to prevent condensation.
Lipid conjugation increases hydrophobicity, which shifts chromatographic retention and can broaden peaks. It also creates additional related species when acylation is incomplete or the chain is oxidised. Methods are therefore developed to separate acylated and non-acylated forms explicitly.
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.